Diamyd Medical Liabilities 2024

Diamyd Medical Aktienanalyse

What does Diamyd Medical do?

Diamyd Medical AB is a Swedish company specializing in the development of therapies for the treatment of autoimmune diseases, particularly type 1 diabetes. The company was founded in 1996 and is headquartered in Stockholm. It commercialized the discovery of Professor Johnny Ludvigsson at Linköping University, who developed a therapy based on the substance GAD (Glutamate Decarboxylase). The company has developed its own GAD-based product called Diamyd®, which is an injection solution that targets the patient's immune system to protect insulin production. In addition to Diamyd®, the company has developed other products based on similar active ingredients, the most important being Remygen®, which combines insulin and GAD to promote insulin production. Diamyd Medical has a broad portfolio of patents and licenses to protect its intellectual property and improve its technologies. The company collaborates closely with other researchers and industry stakeholders to develop and test new therapeutic approaches. Its business model involves licensing its products to pharmaceutical companies and other partners, who then assume responsibility for clinical development and marketing while Diamyd Medical focuses on research and development of new products. The company has expanded into other areas of medicine, including cancer immunotherapy, neurology, and cell therapy. It is currently working on a promising new technology that utilizes Treg cells (regulatory T cells) for the treatment of autoimmune diseases. Diamyd Medical is well-positioned to further expand its market position and drive the development of new therapies. Diamyd Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Diamyd Medical's Liabilities

Diamyd Medical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Diamyd Medical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Diamyd Medical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Diamyd Medical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Diamyd Medical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Diamyd Medical Stock

What is the level of liabilities of Diamyd Medical this year?

Diamyd Medical has a debt balance of 36.41 M SEK this year.

What were the liabilities of Diamyd Medical compared to the previous year?

The liabilities of Diamyd Medical have increased by 64.42% increased compared to the previous year.

What are the consequences of high debt for investors of Diamyd Medical?

High liabilities can pose a risk for investors of Diamyd Medical, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Diamyd Medical?

Low liabilities mean that Diamyd Medical has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Diamyd Medical affect the company?

An increase in liabilities of Diamyd Medical can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Diamyd Medical affect the company?

A decrease in the liabilities of Diamyd Medical can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Diamyd Medical?

Some factors that can influence the liabilities of Diamyd Medical include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Diamyd Medical so important for investors?

The liabilities of Diamyd Medical are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Diamyd Medical take to modify the liabilities?

To change its liabilities, Diamyd Medical can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Diamyd Medical pay?

Over the past 12 months, Diamyd Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diamyd Medical is expected to pay a dividend of 0 SEK.

What is the dividend yield of Diamyd Medical?

The current dividend yield of Diamyd Medical is .

When does Diamyd Medical pay dividends?

Diamyd Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diamyd Medical?

Diamyd Medical paid dividends every year for the past 0 years.

What is the dividend of Diamyd Medical?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diamyd Medical located?

Diamyd Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diamyd Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diamyd Medical from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Diamyd Medical pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Diamyd Medical in the year 2023?

In the year 2023, Diamyd Medical distributed 0 SEK as dividends.

In which currency does Diamyd Medical pay out the dividend?

The dividends of Diamyd Medical are distributed in SEK.